DelSiTech Ltd’s Post

📢Resilience Teams Up with VGXI for Revolutionary Biotech Products 📢 Resilience has chosen VGXI for the supply of pDNA, signaling a promising partnership in the biotech industry. 🤝 VGXI is a leading provider of high-quality plasmid DNA pDNA manufacturing. This collaboration will support the development of innovative biotech products. 💼 #Resilience #VGXI #biotech #BioprocessUpdates #Resilience #VGXI #biotech #partnership #pDNA #manufacturing #innovation #biotechindustry #collaboration #highquality #development #promising #supply #article #industrynews ▷ Read the full article here: 📎 https://lnkd.in/dGAKbWfY

This is what INVESTMENT in your TEAM feels like! It was an honor to work with the CovalX team this month. I want to express my deepest gratitude for their trust in our services. When teams come together to raise standards, increase their skill set, their level of service to support their customers, and feel valued because their company is investing in their future - MAGIC happens! A little background on CovalX.... Many vaccine and drug development companies rely on epitope mapping for regulatory filing of mAbs, but are limited on the speed for filing due to length of time for traditional Crystallography methods. CovalX has created a service that delivers comparable results to crystallography at unprecedented speed, especially for high mass proteins. When you INVEST in a service like this, at every stage of development from early stage to quality control, the confidence you feel about the drugs reproducibility expands and time to filing is reduced. If this service possibility resonates with you - contact them today & find out what connection & support from the PROs feels like! #CovalX #mAbs #epitopemapping #authenticity #magnetism #success #empowered #emotionalintelligence #goals #thespiritofselling #sellmore #emotionalagility #connections #sales #conviction #attitude #innovate #elevate #dowhatyoulove #lovewhatyoudo #distinguish #peakperformance #infinitegame #makeithappen #invest #serve #transform

This is what INVESTMENT in your TEAM feels like! It was an honor to work with the CovalX team this month. I want to express my deepest gratitude for their trust in our services. When teams come together to raise standards, increase their skill set, their level of service to support their customers, and feel valued because their company is investing in their future - MAGIC happens! A little background on CovalX.... Many vaccine and drug development companies rely on epitope mapping for regulatory filing of mAbs, but are limited on the speed for filing due to length of time for traditional Crystallography methods. CovalX has created a service that delivers comparable results to crystallography at unprecedented speed, especially for high mass proteins. When you INVEST in a service like this, at every stage of development from early stage to quality control, the confidence you feel about the drugs reproducibility expands and time to filing is reduced. If this service possibility resonates with you - contact them today & find out what connection & support from the PROs feels like! #CovalX #mAbs #epitopemapping #authenticity #magnetism #success #empowered #emotionalintelligence #goals #thespiritofselling #sellmore #emotionalagility #connections #sales #conviction #attitude #innovate #elevate #dowhatyoulove #lovewhatyoudo #distinguish #peakperformance #infinitegame #makeithappen #invest #serve #transform

"All of us have led and worked for big pharma, bringing CAR-Ts to market. So we understand the complexities of commercialisation, the requirements from the #FDA and the #TGA. So that's the first piece that gives us an edge: is our amazing team. And the second piece is our novel technology. We will be the first company in the world to test the target CDH17 in humans in a CAR-T format, which is really exciting. Similarly, for #chlorotoxin and #glioblastoma, we were the first company to do that as well. Now, everybody's got an NK product, but what makes ours unique is our amazing expansion technology. So we can really have that commercial viability for the off-the-shelf product for the NK program. So, those are four things that set us apart from other companies." Chief Operating Officer Dr. Rebecca McQualter recently spoke with Sharewise to provide an update on the Company and our current trials. Watch the full interview here: https://lnkd.in/gqh-gcgy #CHM #Chimeric #ASX #Biotech

>65K Fragments at your fingertips with Molport library for #FBDD.

Closing the loop on #macrocycles! This wonderful modality continues to evolve, defying the rules of permeability and pushing the boundaries of small molecule #drugdiscovery. From selective #PROTAC warheads, to exquisitely potent inhibitors, these marvellous molecules continue to surprise us with their versatility and properties. Tune into Gerhard Muller and learn about SpiroChem's macrocycle synthesis platform and the QUEST library possibilities! ✨

#IWTeam - 🍁 𝗠𝗲𝗲𝘁 𝗢𝘂𝗿 𝗖𝗮𝗻𝗮𝗱𝗶𝗮𝗻 𝗧𝗲𝗮𝗺! 🍁 📣 This month, we're highlighting Tecniplast Canada, our essential Canadian subsidiary. Meet the dedicated experts behind our innovative solutions! Catch us at Interphex NY and Achema to see our latest developments. ✅ Stay tuned for updates and watch the 📽️ video below 👇 and read the 📑 full article (link in first comment)! #Pharma #TecniplastGroup #CleaningExcellence #InterphexNY #Achema24

Dr. Tse Wen Chang, Chairman and CEO of Immunwork, and Dr. Art Hsing-Mao Chu, CEO of T-E Meds, an affiliate of Immunwork, have been invited to World ADC Asia 2024 in #Korea next week! They will share updates on our innovative tech platforms and drug candidates, with a special focus on our #ADC technologies. Dr. Chu will present "Exploring ADCs With Site-Specific Conjugation, DAR of 8 or 12, & Payloads With Dual Drugs to Turbocharge ADC Innovation," covering: • “CHO-TEM” technology combining CHO Pharma’s glycan modification and T-E Meds’ “Drug Bundles.” • Producing homogeneous ADCs with high DAR (8 or 12) and dual drugs. • Straightforward manufacturing process with great reaction yield. World ADC Asia, the premier ADC conference, gathers top industry leaders to discuss the future of ADC development. Join us in Korea! 🌏🔬 World ADC Event Series #WorldADC #Innovation #Biotech #ADCTechnology #Healthcare

DeciBio's Joe Daccache, Ph.D. and Rebecca Bair are featured in Bioprocess Online's recent article "2023 ADC Roundup: A Year Of Collaboration And Licensing Deals." In this comprehensive piece, Joe and Rebecca Bair dive deep into the intricate details of the antibody-drug conjugates (#ADCs) landscape throughout 2023. Despite a challenging funding climate in biotech, 2023 witnessed a remarkable surge with 76 ADC deals, showcasing the resilience and vibrancy of the industry. From licensing agreements to collaborations and acquisitions, the article sheds light on the diverse transactions that shaped the year. Stay tuned for more exciting ADC content from DeciBio, including the results from the ADC 2024 Industry Outlook Survey. 🌐 Participate in the survey here: https://lnkd.in/e-nn3DEv Click here to access the full article: https://lnkd.in/e-63wYED #Biotech #Innovation #2023Roundup #precisionmedicine #therapeutics #infographic #pharmanews #biotechnews #targetedtherapy #2024outlook

Thoughts on this? >> Former Karuna crew quickly assembles $225M for next neuro bet at Seaport >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #pharmaceutical #productmarketing